Erratum: Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination (Heliyon (2023) 9(4), (S2405844023024489), (10.1016/j.heliyon.2023.e15241))

P Villanueva; NW Crawford; MG Croda; S Collopy; BA Jardim; T de Almeida Pinto Jardim; L Manning; M Lucas; H Marshall; C Prat-Aymerich; A Sawka; K Sharma; D Troeman; U Wadia; A Warris; N Wood; NL Messina; N Curtis; LF Pittet

Journal article

Erratum: Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination (Heliyon (2023) 9(4), (S2405844023024489), (10.1016/j.heliyon.2023.e15241))

P Villanueva, NW Crawford, MG Croda, S Collopy, BA Jardim, T de Almeida Pinto Jardim, L Manning, M Lucas, H Marshall, C Prat-Aymerich, A Sawka, K Sharma, D Troeman, U Wadia, A Warris, N Wood, NL Messina, N Curtis, LF Pittet

Heliyon | Published : 2023

DOI: 10.1016/j.heliyon.2023.e15821

Abstract

The prevalence of scar formation following Bacille Calmette-Guérin (BCG) vaccination varies globally. The beneficial off-target effects of BCG are proposed to be stronger amongst children who develop a BCG scar. Within an international randomised trial (‘BCG vaccination to reduce the impact of coronavirus disease 2019 (COVID-19) in healthcare workers’; BRACE Trial), this nested prospective cohort study assessed the prevalence of and factors influencing scar formation, as well as participant perception of BCG scarring 12 months following vaccination. Amongst 3071 BCG-recipients, 2341 (76%) developed a BCG scar. Scar prevalence was lowest in Spain and highest in UK. Absence of post-injection w..

View full abstract

University of Melbourne Researchers

Paola Villanueva Author

Nigel Crawford Author

Nicole Messina Author

Nigel Curtis Author

Grants

Awarded by Howard and Georgeanna Jones Foundation for Reproductive Medicine

Funding Acknowledgements

We thank the BRACE trial participants for making this study possible. We also thank the researchers involved in establishing the BRACE trial (see Supplemental Material 4 for the BRACE trial Consortium Group) , in particular: Ms. Veronica Abruzzo, Ms. Sonja Elia, Mr. Richard Hall, Ms. Casey Goodall, Dr. Ellie McDonald, Ms. Ann Krastev, Dr. Samantha Bannister, Ms. Grace Gell, Dr. Wendy Norton, Dr. Joyce Chan, A/Prof. Peter Richmond, Prof. Tobias Kollmann, Dr. Susan Hermann, Ms. Erin Latkovic, Ms. Michelle England, Dr. Roberto Oliveira, Dr. Estela Carvalho, Dr. Helen Catterick, Ms. Glauce Dos Santos, Ms. Catriona Doran, Dr. Alison Gifford, Dr. Telma Goldenberg, Dr. Christina Guo, Dr. Georgina Newman, Dr. Ligia Olivio, Dr. Lorrie Symons, Dr. Niki Tan, Dr. Laura Tate, Dr. Tina Zhou. The Murdoch Children's Research Institute (MCRI) leads the BRACE trial across five countries. It is supported by the Victorian Government's Operational Infrastructure Support Programme. The trial is also supported by the Bill & amp; Melinda Gates Foundation [INV-017302] , the Minderoo Foundation [COV-001] , Sarah and Lachlan Murdoch, the Royal Children's Hospital Foundation [2020-1263BRACE Trial] , Health Services Union NSW, the Peter Sowerby Foundation, the Ministry of Health Government of South Australia, the NAB Foundation, the Calvert-Jones Foundation, the Modara Pines Charitable Foundation, the UHG Foundation Pty Ltd, Epworth Healthcare and individual donors. The sponsors had no role in the collection, analysis and interpretation of data or in the preparation, review or approval of the manuscript. P.V. is supported by the Australian Government Research Training Programme Scholarship provided by the Australian Commonwealth Government and the University of Melbourne, and an MCRI Ph.D. Top-Up Scholarship. L.F.P. is supported by the Swiss National Science Foundation [Early Postdoc Mobility Grant, P2GEP3_178155] . N.C. is supported by a National Health and Medical Research Council Investigator Grant [GNT1197117] .